Incidence of pulmonary hypertension and determining factors in patients with systemic sclerosis
- PMID: 29563168
- DOI: 10.1183/13993003.01197-2017
Incidence of pulmonary hypertension and determining factors in patients with systemic sclerosis
Abstract
The objective of this study was to evaluate the incidence of pulmonary hypertension (PH) and determining factors in patients with systemic sclerosis (SSc) and a diffusing capacity of the lung for carbon monoxide (DLCO) <60% predicted.In this bicentric, prospective cohort study, patients with SSc were clinically assessed at baseline and after 3 years, including right heart catheterisation (RHC). Analysis of determining factors for the development of PH was performed using univariate and multivariate analyses.96 patients with a mean pulmonary arterial pressure (mPAP) <25 mmHg at baseline were followed for 2.95±0.7 years (median 3 years). Of these, 71 had a second RHC; 18 of these 71 patients (25.3%) developed PH, and five (7%) developed SSc-associated pulmonary arterial hypertension. For patients with an mPAP of 21-24 mmHg at baseline, the likelihood of presenting with PH as opposed to normal pressures on follow-up was significantly higher (p=0.026). Pulmonary vascular resistance, tricuspid regurgitation velocity, diffusion capacity and the size of the inferior vena cava at baseline were independent predictors for the development of PH during follow-up.In a selected cohort of SSc patients with a DLCO <60%, pulmonary pressures appeared to rise progressively during follow-up. In this population, it was possible to identify manifest PH in almost 25% of patients using prospective RHC during follow-up. Therefore, regular clinical assessment including RHC might be useful in patients with SSc.
Copyright ©ERS 2018.
Conflict of interest statement
Conflict of interest: G. Coghlan received an unrestricted grant to support investigator-led study from Actelion Ltd, during the conduct of the study; and has received lecture fees and travel support from Bayer, lecture and consultancy fees from Actelion, and lecture fees from GSK, outside the submitted work. Conflict of interest: M. Distler has received grants and personal fees from Actelion, Bayer, Boehringer Ingelheim, Pfizer, Sanofi and Novartis, and personal fees from BiogenIdec, ChemomAb, espeRare foundation, Genentech/Roche, GSK, Inventiva, Lilly, medac, MedImmune, Pharmacyclics, Mitsubishi Tanabe Pharma, Sinoxa and UCB, outside the submitted work, to investigate potential treatments of scleroderma and its complications. In addition, M. Distler has a patent mir-29 for the treatment of systemic sclerosis licensed. Conflict of interest: C.P. Denton has received personal fees from Actelion, Bayer, Sanofi-Aventis, Boehringer Ingelheim, Roche, Bristol Myers Squibb and Merck-Serono, and grants and personal fees from GlaxoSmithKline and Inventiva, outside the submitted work. Conflict of interest: M. Doelberg is an employee of Actelion Pharmaceuticals Ltd. Conflict of interest: S. Harutyunova has received personal fees from Bayer, MSD, Actelion and GSK, outside the submitted work. Conflict of interest: A.M. Marra has received personal fees from Bayer, outside the submitted work. Conflict of interest: N. Benjamin has received lecture fees and travel support from Bayer, and lecture fees from Actelion, outside the submitted work. Conflict of interest: E. Grünig has received fees for lectures and/or consultations from Actelion, Bayer/MSD, GSK, United Therapeutics and Pfizer.
Comment in
-
Identifying early pulmonary arterial hypertension in patients with systemic sclerosis.Eur Respir J. 2018 Apr 4;51(4):1800495. doi: 10.1183/13993003.00495-2018. Print 2018 Apr. Eur Respir J. 2018. PMID: 29618608 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources